Anaptysbio (ANAB) Amortizatization of Intangibles (2020 - 2026)
Anaptysbio (ANAB) reported Amortizatization of Intangibles of $480000.0 for Q1 2026, up 4.35% on a YoY basis from $460000.0 in Q1 2025, and up 1.05% quarter-over-quarter from $475000.0 in Q4 2025.
Anaptysbio (ANAB) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Anaptysbio has reported Amortizatization of Intangibles for 7 years, with the latest figure at $480000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 4.35% year-over-year to $480000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 4.15% YoY), and the FY2025 full-year result was $1.9 million, up 4.08% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $480000.0, up from $475000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $876000.0 in Q4 2022, with the low at -$161000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $442294.1 across 5 years, with a median of $452000.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles plunged 227.78% — and 2023, when it jumped 365.22%.
- Anaptysbio's Amortizatization of Intangibles stood at $876000.0 in 2022, then sank by 49.89% to $439000.0 in 2023, then climbed by 3.87% to $456000.0 in 2024, then climbed by 4.17% to $475000.0 in 2025, then increased by 1.05% to $480000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $480000.0 (Q1 2026), $475000.0 (Q4 2025), and $470000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | 480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Dec 31, 2023 | 439,000.00 |